Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in progression ...
Three unrelated issues prompt a trio of recalls by the NHTSA, and one of them will only be fixed in March 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback